For instance, Nutlin-3a, an MDM2 antagonist that acts as p53 activator, decreases the expression of integrin alpha5 in colorectal cancer and glioma cells [21,22]; also the expression of integrin beta3 decreases upon DNA-damage in wild-type p53 expressing cells [23]. This evidence concerns the gene TP53 and central nervous system cancer.